Molecular radiotherapy using cleavable radioimmunoconjugates that target EGFR and γH2AX.
Many anticancer therapies, including ionizing radiation (IR), cause cytotoxicity through generation of DNA double-strand breaks (DSB). Delivery of therapeutic radionuclides to DNA DSB sites can amplify this DNA damage, for additional therapeutic gain. Herein, we report on two radiopharmaceuticals, r...
Príomhchruthaitheoirí: | Cornelissen, B, Waller, A, Able, S, Vallis, K |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
American Association for Cancer Research
2013
|
Míreanna comhchosúla
Míreanna comhchosúla
-
Molecular radiotherapy using cleavable radioimmunoconjugates that target eGFR and γH2AX
de réir: Cornelissen, B, et al.
Foilsithe / Cruthaithe: (2013) -
Can γH2AX be used to personalise cancer treatment?
de réir: Shah, K, et al.
Foilsithe / Cruthaithe: (2013) -
Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical
de réir: Cornelissen, B, et al.
Foilsithe / Cruthaithe: (2012) -
Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical.
de réir: Cornelissen, B, et al.
Foilsithe / Cruthaithe: (2012) -
γH2AX expression in cytological specimens as a biomarker of response to radiotherapy in solid malignancies
de réir: Shah, K, et al.
Foilsithe / Cruthaithe: (2015)